In this strain Cre-ERT2 is knocked into the translational start site of the Lrig1 (leucine-rich repeats and immunoglobulin-like domains 1) gene. This strain may be useful for mediating inducible cre recombination in Lrig1 expressing tissues, and for applications in lineage mapping proliferative and quiescent intestinal progenitor cells.
Dr. Robert J. Coffey, Vanderbilt University Medical Center
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Recombinase-expressing, Inducible) | Lrig1 | leucine-rich repeats and immunoglobulin-like domains 1 |
Lrig1 (leucine-rich repeats and immunoglobulin-like domains 1) encodes a transmembrane protein that negatively regulates ErbB receptors, Met and Ret, and is a marker for intestinal and skin progenitor cells. These Lrig1-CreERT2 mice carry a targeted mutation in which Cre-ERT2 is knocked into the endogenous ATG site of the Lrig1 gene. Although homozygotes are viable and fertile on the mixed B6;129 background, by 6 months of age homozygotes develop duodenal adenomas and some homozygous females exhibit impaired lactation. Homozygotes on the congenic C57BL/6 background exhibit an embryonic lethal phenotype. Heterozygotes are viable and fertile. These mice display robust inducible Cre recombination activity at a greater efficiency than that seen in Lgr5-EGFP-IRES-CreERT2 mice (Stock No. 008875). The Cre-ERT2 fusion protein is only active when it binds to the estrogen analog 4-hydroxytamoxifen (OHT). When these mice are bred with mice containing a loxP-flanked sequence, tamoxifen-inducible Cre-mediated recombination is expected to result in deletion of the floxed sequences in the Cre recombinase and Lrig1 expressing quiescent intestinal, gastric epithelium and skin progenitor cells of the offspring.
A targeting vector designed by Dr. Robert J. Coffey (Vanderbilt University) containing sequence encoding Cre recombinase-estrogen receptor (Cre-ERT2) fusion protein, SV40 polyA signal, and an FRT-flanked PGK-neo cassette was inserted immediately after the endogenous ATG site of Lrig1. The construct was electroporated into 129S6/SvEvTac derived TL1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into blastocysts. The resulting chimeric animals were crossed to B6.Cg-Tg(ACTFLPe)9205Dym/J (Stock No. 005703) mice to remove the FRT site flanked NEO cassette. Upon arrival at The Jackson Laboratory, the mice were crossed to C57BL/6J (Stock No. 000664) at least once to establish the colony.
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
---|---|
Site of Expression | Intestinal colonic stem cells located at the crypt base. |
Allele Name | targeted mutation 1.1, Robert J Coffey |
---|---|
Allele Type | Targeted (Recombinase-expressing, Inducible) |
Allele Synonym(s) | Lrig1-CreERT2 |
Gene Symbol and Name | Lrig1, leucine-rich repeats and immunoglobulin-like domains 1 |
Gene Synonym(s) | |
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
Site of Expression | Intestinal colonic stem cells located at the crypt base. |
Strain of Origin | 129S6/SvEvTac |
Chromosome | 6 |
Molecular Note | The targeting vector used for homologous recombination was generated by BAC recombineering. A tamoxifen-inducible cre (cre/ERT2) sequence, SV40 polyA signal, and an Frt-flanked PGK-neo cassette were targeted to the endogenous ATG site of Lrig1. Chimeras were crossed with Flpe-expressing animals to remove the neo from the germline. |
When maintaining a live colony, these mice can be bred as heterozygotes. Homozygotes on the congenic C57BL/6 background are not viable.
When using the Lrig1-CreERT2 mouse strain in a publication, please cite the originating article(s) and include JAX stock #018418 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Heterozygous or wildtype for Lrig1<tm1.1(cre/ERT2)Rj |
Frozen Mouse Embryo | STOCK Lrig1<tm1.1(cre/ERT2)Rjc/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | STOCK Lrig1<tm1.1(cre/ERT2)Rjc/J Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | STOCK Lrig1<tm1.1(cre/ERT2)Rjc/J Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | STOCK Lrig1<tm1.1(cre/ERT2)Rjc/J Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.